Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BHQ880 plus zoledronic acid in relapsed/refractory multiple myeloma with prior skeletal complications
2008-000411-15Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple myeloma (MM) comparing BHQ880 plus zoledronic acid with Placebo plus zoledronic acid (2 arms). Primary endpoint: Safety endpoints. Started Feb 2009; status: completed.
02
Drugs
BHQ880
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-000411-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000411-15.